Skip to main content
The words approved in red and spelled out in capitals.

Cipla obtains FDA OK for generic Brovana

Brovana had a market value of approximately $438 million for the 12-month period ending April 2021, according to IQVIA.
Levy

Cipla has received the Food and Drug Administration’s blessing for arformoterol tartrate inhalation solution 15 mcg/2 ml.

The medication is the generic of Sunovion’s Brovana.

Brovana is a long-acting beta-2 adrenergic agonist (beta-2 agonist) indicated for long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

Brovana had a market value of approximately $438 million for the 12-month period ending April 2021, according to IQVIA.

The product is available for shipping. 

X
This ad will auto-close in 10 seconds